Enliven Therapeutics Inc. (ELVN)
22.16
1.70 (8.31%)
At close: Jan 15, 2025, 10:58 AM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 297.00K | 622.00K | 99.00K | 97.00K | 33.00K | n/a | n/a |
| Gross Profit | -297.00K | -622.00K | -99.00K | -97.00K | -33.00K | n/a | n/a |
| Operating Income | -83.53M | -38.79M | -24.76M | -9.32M | -24.12M | -10.68M | -8.90M |
| Interest Income | 11.97M | 1.13M | 22.00K | 31.00K | 578.00K | n/a | n/a |
| Pretax Income | -71.58M | -37.66M | -24.74M | -18.97M | -23.46M | -11.34M | 221.00K |
| Net Income | -71.58M | -37.75M | -24.72M | -18.93M | -23.46M | -11.34M | n/a |
| Selling & General & Admin | 18.95M | 7.77M | 4.29M | 1.08M | 5.07M | 2.44M | 987.00K |
| Research & Development | 64.57M | 31.02M | 20.47M | 8.24M | 19.01M | 8.24M | 7.92M |
| Other Expenses | n/a | n/a | n/a | -9.68M | n/a | n/a | n/a |
| Operating Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.08M | 10.68M | 8.90M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -33.00K | n/a | n/a |
| Cost & Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.12M | 10.68M | 8.90M |
| Income Tax | n/a | 88.00K | -22.00K | -31.00K | 653.00K | -821.14K | 221.00K |
| Shares Outstanding (Basic) | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
| Shares Outstanding (Diluted) | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
| EPS (Basic) | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | n/a |
| EPS (Diluted) | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | n/a |
| EBITDA | -81.93M | -38.58M | -24.65M | -9.27M | -23.43M | -11.34M | 221.00K |
| Depreciation & Amortization | 297.00K | 215.00K | 115.00K | 97.00K | 33.00K | -660.00K | n/a |